Amgen to buy Celgene ’s Otezla in $13.4bn deal

The sale of Otezla is part of an effort by Bristol-Myers Squibb to divest assets to win regulatory approval for its previously agreed $90 billion takeover of rival biotech giant Celgene.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 26, 2019 Category: Pharmaceuticals Authors: By James Fontanella-Khan and Eric Platt in New York Source Type: news